A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP) (OPTIMA-2)
Phase 3 Evaluation of the Safety, Pharmacokinetics, and Efficacy of Garetosmab (Anti-Activin A Monoclonal Antibody) in Children and Adolescents With Fibrodysplasia Ossificans Progressiva
This study is researching an experimental drug called garetosmab, referred to as "study drug". The study is focused on children and adolescent participants with FOP. For United States: Ages 4 to less than 18 years; for non-US sites only: Ages 2 to less than 18 years.
The aim of the study is to see how safe, tolerable, and effective the study drug is.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Clinical Trials Administrator
- Número de teléfono: 844-734-6643
- Correo electrónico: clinicaltrials@regeneron.com
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Key Inclusion Criteria:
-
For USA participants, age criteria are 4 to < 18 years old, at the time of the administration of the first dose of study intervention. Non-USA participants age criteria are 2 to < 18 years old
-
Must have a confirmation of FOP diagnosis, as described in the protocol
-
At the time of enrollment, participants must weight:
- Cohort 1: more than 30 kg (or 66.1 pounds)
- Cohort 2: more than 30 kg (or 66.1 pounds)
- Cohort 3: less than or equal to 30 kg (or 66.1 pounds)
Key Exclusion Criteria:
- Cumulative Analog Joint Involvement Scale (CAJIS) score > 19 at the time of screening
- Participant has significant concomitant illness or history of significant illness, as described in the protocol
- Previous history or diagnosis of cancer
- Ongoing significant viral or bacterial illness, within 2 weeks of the first study drug administration
- History of severe respiratory compromise requiring oxygen, respiratory support
- Known history of cerebral vascular malformation
- Participants with a history of severe, non-traumatic bleeding requiring transfusion or hospitalization for hemodynamic compromise
- Participants with a known pre-existing medical history of a bleeding diathesis, as described in the protocol
- Participants who have used palovarotene in the last 30 days or within 5 half-lives of the therapy, whichever is longer from the day of randomization
NOTE: Other Protocol-defined Inclusion/Exclusion Criteria Apply
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Cohort 1: Adolescents
Participants aged 12 - 18 years old |
Administered per the protocol
Otros nombres:
|
|
Experimental: Cohort 2: Children
Children who are 4 to 12 years old (for non-US sites only 2 to 12 years old) |
Administered per the protocol
Otros nombres:
|
|
Experimental: Cohort 3: Children and Adolescents
Participants and Children aged 4 to 18 years old (for non-US sites only 2 to 18 years old) |
Administered per the protocol
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Severity of TEAEs
Periodo de tiempo: Baseline to week 56
|
Baseline to week 56
|
|
Concentrations of functional garetosmab in serum
Periodo de tiempo: Through week 56
|
Through week 56
|
|
Occurrence of Treatment-Emergent Adverse Event (TEAEs)
Periodo de tiempo: Baseline to week 56
|
Baseline to week 56
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of new HO lesions
Periodo de tiempo: At week 28 and week 56
|
At week 28 and week 56
|
|
|
Occurrence of new HO lesions
Periodo de tiempo: At week 28 and week 56
|
At week 28 and week 56
|
|
|
Number of clinician-assessed flare-ups
Periodo de tiempo: Through week 28 and week 56
|
Through week 28 and week 56
|
|
|
Occurrence of clinician-assessed flare-ups
Periodo de tiempo: Through week 28 and week 56
|
Through week 28 and week 56
|
|
|
Characteristics of menstrual cycles for female participants who reached menarche
Periodo de tiempo: Over 28 weeks and 56 weeks
|
Over 28 weeks and 56 weeks
|
|
|
Concentrations of total activin A in serum
Periodo de tiempo: Through week 56
|
Through week 56
|
|
|
Occurence of Anti-Drug Antibody (ADA) to garetosmab
Periodo de tiempo: Through week 56
|
Through week 56
|
|
|
Magnitude of ADA to garetosmab
Periodo de tiempo: Through week 56
|
Through week 56
|
|
|
Change from baseline in hearing function as assessed by audiometry
Periodo de tiempo: At week 28 and week 56
|
At week 28 and week 56
|
|
|
Total volume of new Heterotopic Ossification (HO) lesions
Periodo de tiempo: At week 28 and week 56
|
At week 28 and week 56
|
|
|
Change from baseline in total volume of HO lesions
Periodo de tiempo: At week 28 and week 56
|
At week 28 and week 56
|
|
|
Change from baseline in Tanner puberty scale
Periodo de tiempo: At week 28 and week 56
|
Tanner puberty scale or stages: Staging of sexual development is graded on a 5-point ordinal scale ranging from 1 (prepubertal) to 5 (adultlike) for female breast development, male external genitals, and pubic hair |
At week 28 and week 56
|
|
Height-for-age Z-Scores according to the World Health Organization (WHO) Growth Reference Data for Children
Periodo de tiempo: Through week 56
|
Participants 5-19 years of age Z-score represents standardized measure of how far an individual deviated from study cohort average at baseline. A higher Z-score reflects better performance. |
Through week 56
|
|
Change from baseline in knee height
Periodo de tiempo: At week 28 and week 56
|
At week 28 and week 56
|
|
|
Change from baseline in Pediatric Quality of Life inventory (PedsQL) scores
Periodo de tiempo: At week 28 and week 56
|
Age-appropriate PedsQL Generic Core Scales will be used to measure HRQoL in children and adolescents. Response options include 5-point Likert scale (or 3-point Likert scale for the young children self-report) for each item asking about experience within the past week. Global scores are transformed to a 0 to 100 scale with higher scores indicating better quality of life. |
At week 28 and week 56
|
|
Acceptability or tolerability assessment via exit interview
Periodo de tiempo: Up to week 52
|
Each interview will be conducted by trained external interviewers following a semi-structured interview guide of questions for the participants about their overall experience in the trial. |
Up to week 52
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Director de estudio: Clinical Trial Management, Regeneron Pharmaceuticals
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
- Displasia esquelética
- Miositis Osificante Progresiva
- Osificación heterotópica
- ACVR1
- ACVR1 Mutation
- Activin A Receptor Type 1
- ALK2 Mutation
- Fibrodysplasia Ossificans Congenita
- FOP-causing Mutation
- Münchmeyer Disease
- Progressive Heterotopic Ossification
- Progressive Myositis Ossificans
- Stone Man Disease
Términos MeSH relevantes adicionales
- Enfermedades musculoesqueléticas
- Enfermedades Musculares
- Procesos Patológicos
- Metabolismo, errores congénitos
- Enfermedades Genéticas Congénitas
- Enfermedades metabólicas
- Enfermedades del tejido conectivo
- Metabolismo de carbohidratos, errores congénitos
- Enfermedades de almacenamiento lisosomal
- Mucinosis
- Miositis
- Mucopolisacaridosis
- Enfermedades y anomalías congénitas, hereditarias y neonatales
- Condiciones Patológicas, Signos y Síntomas
- Enfermedades Nutricionales y Metabólicas
- Enfermedades de la piel y del tejido conectivo
- Miositis osificante
- Mucopolisacaridosis IV
- Osificación Heterotópica
Otros números de identificación del estudio
Otros números de identificación del estudio
- R2477-FOP-2413
- 2024-518415-19-01 (Ctis)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
Marco de tiempo para compartir IPD
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
Criterios de acceso compartido de IPD
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
- CÓDIGO_ANALÍTICO
- RSC
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .